razpipadon (CVL-871) / AbbVie - LARVOL DELTA

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy (clinicaltrials.gov) - P2 | N=41 | Completed | Sponsor: Cerevel Therapeutics, LLC | Active, not recruiting ➔ Completed | N=75 ➔ 41

Enrollment change • Trial completion • Alzheimer's Disease • CNS Disorders • Dementia

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy (clinicaltrials.gov) - P2 | N=75 | Active, not recruiting | Sponsor: Cerevel Therapeutics, LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Feb 2025 | Trial primary completion date: Oct 2024 ➔ Jan 2025

Enrollment closed • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Cerevel Therapeutics, LLC | Trial completion date: Jun 2023 ➔ Oct 2024 | Trial primary completion date: Jun 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire) - “Emraclidine: Cerevel is conducting two adequately-powered placebo-controlled Phase 2 trials, known as EMPOWER-1 and EMPOWER-2. Enrollment for these trials is on track and data for both trials are expected in the first half of 2024….Tavapadon: a D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease….Following a detailed review of all environmental factors, Cerevel now expects data from TEMPO-3 in mid-year 2024 and TEMPO-1 and TEMPO- 2 in the second half of 2024. CVL-871: a D1/D5 partial agonist in development for treatment of dementia-related apathy. Cerevel is conducting a Phase 2a exploratory trial in dementia-related apathy…data is now expected for this trial in the second half of 2024.”

P2 data • P2a data • P3 data • CNS Disorders • Dementia • Parkinson's Disease • Schizophrenia

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Cerevel Therapeutics, LLC | Trial completion date: Sep 2022 ➔ Jun 2023 | Trial primary completion date: Jun 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy (clinicaltrials.gov) - P2; N=75; Recruiting; Sponsor: Cerevel Therapeutics, LLC; Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Dementia

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy (clinicaltrials.gov) - P2; N=75; Not yet recruiting; Sponsor: Cerevel Therapeutics, LLC

Clinical • New P2 trial • Alzheimer's Disease • CNS Disorders • Dementia